SPIRIT 1: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Administered With and Without Low-Dose Estradiol and Norethindrone Acetate in Women With Endometriosis-Associated Pain
Phase of Trial: Phase III
Latest Information Update: 03 Jul 2018
At a glance
- Drugs Relugolix (Primary)
- Indications Pain
- Focus Registrational; Therapeutic Use
- Acronyms SPIRIT 1
- Sponsors Myovant Sciences
- 08 Sep 2017 Status changed from not yet recruiting to recruiting.
- 28 Jun 2017 Status changed from planning to not yet recruiting.
- 07 May 2017 According to a Myovant Sciences media release, Company plans to initiate this trial in the second quarter of 2017.